Play all audios:
In April 2009, efalizumab was withdrawn from the market for the treatment of psoriasis after reports emerged of an association between long-term therapy and the development of progressive
multifocal leukoencephalopathy (PML). This event highlights an urgent need for greater awareness and research into the screening, diagnosis and treatment of this potentially fatal disease in
patients undergoing immunosuppressive therapy for chronic inflammatory disorders. Access through your institution Buy or subscribe This is a preview of subscription content, access via your
institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this
article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in
* Learn about institutional subscriptions * Read our FAQs * Contact customer support REFERENCES * US Food and Drug Administration _FDA public health advisory: updated safety information
about Raptiva (efalizumab)_ [online] (2009). * US Food and Drug Administration _FDA approves updated labeling for psoriasis drug Raptiva: safety concerns drove labeling change_ [online]
(2009). * Calabrese, L. H., Molloy, E. S., Huang, D. & Ransohoff, R. M. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of
disease. _Arthritis Rheum._ 56, 2116–2128 (2007). Article PubMed Google Scholar * Molloy, E. S. & Calabrese, L. H. Progressive multifocal leukoencephalopathy in patients with
rheumatic diseases: are patients with systemic lupus erythematosus at particular risk? _Autoimmun. Rev._ 8, 144–146 (2008). Article CAS PubMed Google Scholar * Calabrese, L. H. &
Molloy, E. S. Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies. _Ann. Rheum. Dis._ 67 (Suppl. 3),
iii64–iii65 (2008). PubMed Google Scholar * Molloy, E. S. & Calabrese, L. H. Progressive multifocal leukoencephalopathy—a national estimate of frequency in SLE and other rheumatic
diseases. _Arthritis Rheum._ 58, S637 (2008). Article Google Scholar * Ransohoff, R. M. Natalizumab and PML. _Nat. Neurosci._ 8, 1275 (2005). Article CAS PubMed Google Scholar Download
references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Cleveland Clinic, Cleveland, OH, USA Eamonn S. Molloy & Leonard H. Calabrese Authors * Eamonn S. Molloy View author publications
You can also search for this author inPubMed Google Scholar * Leonard H. Calabrese View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR
Correspondence to Eamonn S. Molloy. ETHICS DECLARATIONS COMPETING INTERESTS E. S. Molloy declares no competing interests. L. H. Calabrese has acted as a consultant for the following
companies: Genentech, Wyeth, Biogen and Roche. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Molloy, E., Calabrese, L. Targeted but not trouble-free:
efalizumab and PML. _Nat Rev Rheumatol_ 5, 418–419 (2009). https://doi.org/10.1038/nrrheum.2009.142 Download citation * Issue Date: August 2009 * DOI:
https://doi.org/10.1038/nrrheum.2009.142 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not
currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative